You can buy or sell ZOM and other stocks, options, ETFs, and crypto commission-free!
Zomedica Pharmaceuticals Corp. engages in the discovery, development and commercialization of pharmaceuticals for the companion pet. The company was founded by Gerald L. Read More Solensky, Jr. on January 7, 2013 and is headquartered in Ann Arbor, MI.
Ann Arbor, Michigan
52 Week High
52 Week Low
Stock Price, News, & Analysis for Zomedica Pharmaceuticals
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transder...
Markets InsiderFeb 26
Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results
ANN ARBOR, Mich., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). “We made major strides in 2018 to expand our diagnostic pi...
Expected May 9, Pre-Market